Abstract
Summary
KEY FINDINGS
The Europe veterinary vaccines market growth is estimated to propel with a CAGR of 6.97% during the forecast period, 2022-2030. The market growth is driven by huge foreign investments, research and development, innovations in the field, and advanced vaccine production.
MARKET INSIGHTS
The Europe veterinary vaccines market growth assessment includes the analysis of Germany, Italy, Belgium, the United Kingdom, France, Russia, Poland, and Rest of Europe. In Italy, several public health institutions are formed to control and improve animal health, protect animal welfare, control animal breeding to ensure high quality animal production, and feedstuffs safety to protect consumers' health. All these initiatives require large supplies of veterinary vaccines, contributing to the market growth in the region.
Additionally, in March 2021, the government of Russia announced that it had registered for the world's first animal-specific jab. As per reports, vaccination drives have already started at veterinary clinics all around the country.
Moreover, in Poland, livestock animals play an important part in the agriculture sector, since the latter is a significant contributor to market growth. The livestock is used for farming purposes, dairy and meat production, and exports. Therefore, animal producers need to sustain animal health. As a result, it offers veterinary vaccine companies immense opportunities to provide vaccines to keep safe livestock lifelong, thereby boosting the market growth.
COMPETITIVE INSIGHTS
Some key market players include Boehringer Ingelheim International GmbH, Indian Immunologicals Limited, Vaxxinova GmbH, Hester Biosciences Ltd, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
1 RESEARCH SCOPE & METHODOLOGY
1.1 STUDY OBJECTIVES
1.2 SCOPE OF STUDY
1.3 METHODOLOGY
1.4 ASSUMPTIONS & LIMITATIONS
2 EXECUTIVE SUMMARY
2.1 MARKET SIZE & ESTIMATES
2.2 MARKET OVERVIEW
3 MARKET DYNAMICS
3.1 KEY DRIVERS
3.1.1 RESEARCH & DEVELOPMENT OF ADVANCED VACCINES
3.1.2 NEED OF VACCINE DUE TO RISING ANIMAL POPULATION AND DISEASES
3.1.3 VACCINATION DRIVES BY GOVERNMENT AGENCIES
3.2 KEY RESTRAINTS
3.2.1 RULES & REGULATIONS FOR THE USE OF VACCINE
3.2.2 LACK OF AWARENESS AMONG FARMERS AND REQUIREMENT OF SKILLED VETERINARIANS
4 KEY ANALYTICS
4.1 IMPACT OF COVID-19 ON VETERINARY VACCINES MARKET
4.2 KEY MARKET TRENDS
4.3 PORTER'S FIVE FORCES ANALYSIS
4.3.1 BUYERS POWER
4.3.2 SUPPLIERS POWER
4.3.3 SUBSTITUTION
4.3.4 NEW ENTRANTS
4.3.5 INDUSTRY RIVALRY
4.4 VALUE CHAIN ANALYSIS
4.5 KEY BUYING CRITERIA
4.6 REGULATORY FRAMEWORK
5 MARKET BY ANIMAL TYPE
5.1 LIVESTOCK ANIMAL
5.1.1 CATTLE
5.1.2 PIGS
5.1.3 POULTRY
5.1.4 SHEEP
5.1.5 OTHER LIVESTOCK ANIMALS
5.2 COMPANION ANIMAL
5.2.1 CANINE
5.2.2 FELINE
5.2.3 EQUINE
5.3 AQUACULTURE
6 MARKET BY PRODUCT TYPE
6.1 ATTENUATED VACCINES
6.2 INACTIVATED VACCINES
6.3 TOXOID VACCINES
6.4 CONJUGATE VACCINES
6.5 DNA VACCINES
6.6 RECOMBINANT VACCINES
6.7 SUBUNIT VACCINES
7 MARKET BY DISEASE TYPE
7.1 CANINE DISEASE
7.2 PORCINE DISEASE
7.3 BOVINE DISEASE
7.4 POULTRY DISEASE
7.5 AQUACULTURE DISEASE
7.6 OTHER DISEASES
8 GEOGRAPHICAL ANALYSIS
8.1 EUROPE
8.1.1 MARKET SIZE & ESTIMATES
8.1.2 KEY GROWTH ENABLERS
8.1.3 KEY CHALLENGES
8.1.4 KEY PLAYERS
8.1.5 COUNTRY ANALYSIS
- 8.1.5.1 UNITED KINGDOM
- 8.1.5.2 GERMANY
- 8.1.5.3 FRANCE
- 8.1.5.4 ITALY
- 8.1.5.5 RUSSIA
- 8.1.5.6 BELGIUM
- 8.1.5.7 POLAND
- 8.1.5.8 REST OF EUROPE
9 COMPETITIVE LANDSCAPE
9.1 KEY STRATEGIC DEVELOPMENTS
9.1.1 MERGERS & ACQUISITIONS
9.1.2 PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3 PARTNERSHIPS & AGREEMENTS
9.1.4 BUSINESS EXPANSIONS & DIVESTITURES
9.2 COMPANY PROFILES
9.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
9.2.2 BRILLIANT BIO PHARMA
9.2.3 CEVA SANTE ANIMALE
9.2.4 ELANCO ANIMAL HEALTH
9.2.5 HESTER BIOSCIENCES LTD
9.2.6 HIPRA
9.2.7 INDIAN IMMUNOLOGICALS LIMITED
9.2.8 MERCK ANIMAL HEALTH
9.2.9 PHIBRO ANIMAL HEALTH
9.2.10 VAXXINOVA GMBH
9.2.11 VIRBAC SA
9.2.12 ZOETIS